Current News

Contact | Print version | Send article | RSS feed

KINAXO enters into agreement with Schering AG on kinase inhibitor profiling

31 Jul 2006 - KINAXO Biotechnologies GmbH has entered into a services and collaboration agreement with Schering AG. Under the agreement, KINAXO will employ the KinaTor(TM) technology to perform selectivity analyses for Schering AG's small molecule kinase inhibitors. The results of this study will support Schering AG's lead optimization activities in the field of kinase inhibitors.
 
"We are delighted to enter into this collaboration with Schering AG. It underlines the benefits of our technology platform for developing the next generation of kinase inhibitors," said Dr. Andreas Jenne, CEO of KINAXO. "The KinaTorTM technology permits rational decisions based on proteome-wide selectivity data and greatly facilitates the development of clean and spectrum-selective kinase drugs with well-characterized inhibition profiles."
 
The KinaTor(TM) technology uses immobilized kinase inhibitors to detect their protein binding partners in cell lines or tissue samples. Affinity-based separation procedures in combination with sensitive mass spectrometry and biochemical assays allow KINAXO to identify and quantify the protein-small molecule interactions of kinase inhibitors.